Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity

Bibliography

• REED E: Cisplatin. Cancer Chemother. Biol. Response Modif (1999) 18:144–151.
   PubMedGoogle Scholar
• SPINGLER B, WHITTINGTON DA, LIPPARD SJ: 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg. Chem. (2001) 40:5596–5602.
   Google Scholar
• BURGER H, NOOTER K, BOERSMA AW, KORTLAND CJ, STOTER G: Expression of p53, Bc1-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br. Cancer (1998) 77:1562–1567.
   Web of Science ®Google Scholar
• PEREZ RP: Cellular and molecular determinants of cisplatin resistance. Eur..1. Cancer (1998) 34:1535–1542.
   PubMed Web of Science ®Google Scholar
• KELLAND LR: Preclinical perspectives on platinum resistance. Drugs (2000) 59\(Suppl. 4):1–8.
   Google Scholar
• GIACCONE G: Clinical perspectives on platinum resistance. Drugs (2000) 59\(Suppl. 4):9–17.
   Google Scholar
• MACARA IG: Vanadium - an element in search of a role. Trends Biochem. Si". (1980) 5:92–94.
   Google Scholar
• REHDER D: The bioinorganic chemistry of vanadium. Angew. Chem. Int. Ed. Engl. (1991) 130:148–167.
   Web of Science ®Google Scholar
• BOYD DW, KUSTIN K: Vanadium: a versatile biochemical effector with an elusive biological function. Adv. Inorg. Biochem. (1984) 6:311–365.
   PubMedGoogle Scholar
• RUBINSON KA: Concerning the form of biochemically active vanadium. Proc. R. Soc. Lond. B Biol. Sci. (1981) 212:65–84.
   PubMed Web of Science ®Google Scholar
• POSNER BI, FAURE R, BURGESS JW et al.: Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics. Biol. Chem. (1994) 269:4596–4604.
   Google Scholar
• SAUCE VC, CORTIZO AM, GOMEZ DUMM CL, ETCHEVERRY SB: Tyrosine phosphorylation and morphological transformation induced by four vanadium compounds on MC3T3E1 cells. Ma Cell Biochem. (1999) 198:119–128.
   PubMed Web of Science ®Google Scholar
• LIOCHEV S, IVANCHEVA E: Vanadyl causes hydroxyl radical mediated degradation of deoxyribose. Free Radic. Res. Commun. (1991) 14:335–342.
   PubMed Web of Science ®Google Scholar
• SHI X, JIANG H, MAO Y, YE J, SAFFIOTTI U: Vanadium(IV)-mediated free radical generation and related 2'-deoxyguanosine hydroxylation and DNA damage. Toxicology (1996) 106:27–38.
   PubMed Web of Science ®Google Scholar
• HUANG C, ZHANG Z, DING M et al.:Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis. Biol Chem. (2000) 275:32516–32522.
   Web of Science ®Google Scholar
• KOPF-MAIER P, KOPF H: Non-platinum-group metal antitumor agents: history, current status, and perspectives. Chem. Rev (1987) 87:1137–1152.
   Web of Science ®Google Scholar
• •Comprehensive review discussing the clinical potential of early-transition metal complexes found to be effective against experimental tumours in animals.
   Google Scholar
• DJORDJEVIC C,WAMPLER GL: Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium.' Inorg. Biochem. (1985) 25:51–55.
   PubMed Web of Science ®Google Scholar
• KOPF-MAIER P, KOPF H: Transition and main-group metal cyclopentadienyl complexes: Preclinical studies on a series of antitumor agents of different structural type. Structure Bonding (1988) 70:103–185.
   Google Scholar
• KOPF-MAIER P: Antitumor bis(cyclopentadieny0 metal complexes. In: Metal Complexes in Cancer Chemotherapy Keppler BK (Ed.), VCH Publishers, New York (1993):259–296.
   Google Scholar
• GHOSH P, D'CRUZ 0J, NARLA RK, UCKUN FM: Apoptosis-inducing vanadocene compounds against human testicular cancer. Gin. Cancer Res. (2000) 6:1536–1545.
   Web of Science ®Google Scholar
• •In vitro studies indicated that bis(cydopentadienyl) complexes of vanadium(IV) have broad-spectrum anticancer activity and induce apoptosis in human leukaemia cells as well as cells derived from human solid tumours.
   Google Scholar
• KUO YL, LIU AH, MARKS TJ: Metallocene interactions with DNA and DNA-processing enzymes. In: Metal Ions M Biological Systems. Sigel H (Ed.), Marcel Dekker, New York (1996) :53–85.
   Google Scholar
• HARDING MM, MOKDSI G: Antitumour metallocenes: structure-activity studies and interactions with biomolecules. Curr. Med. Chem. (2000) 7:1289–1303.
   PubMed Web of Science ®Google Scholar
• D'CRUZ 0J, DONG Y, UCKUN FM: Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer. Anti-Cancer Drugs (2000) 11:849–858.
   PubMed Web of Science ®Google Scholar
• •This study evaluated the in vitro anticancer activity of 15 oxovanadium(IV) complexes against cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines and identified metvan as the most potent cytotoxic and apoptosis-inducing oxovanadium(IV) compound against ovarian cancer.
   Google Scholar
• NARLA RK, DONG Y, D'CRUZ 0J, NAVARA C, UCKUN FM: Bis(4,7-dimethy1-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel apoptosis-inducing anticancer agent. Gin. Cancer Res. (2000) 6:1546–1556.
   Web of Science ®Google Scholar
• •This study indicated that substituted and bis-chelated oxovanadium (IV) complexes have broad-spectrum anticancer activity and induce apoptosis in human leukaemia cells and solid tumour cell lines. Metvan was identified as the lead oxovanadium compound.
   Google Scholar
• NARLA RK, DONG Y, KLIS D, UCKUN FM: Bis(4,7-dimethy1-1,10-phenanthroline) sulfatooxovanadium(IV) as a novel antileukemic agent with matrix metalloproteinase inhibitory activity. Clin. Cancer Res. (2001) 7:1094–1101.
   PubMed Web of Science ®Google Scholar
• •In vitro studies indicated that metvan is a potent antileukaemic agent with antiadhesive and anti-invasive properties against primary leukaemia cells from patients with ALL, AML and CML.
   Google Scholar
• DONG Y, NARLA RK, SUDBECK E, UCKUN FM: Synthesis, X-ray structure, and anti-leukemic activity of oxovanadium(IV) complexes. Inorg. Biochem. (2000) 78:321–330.
   PubMed Web of Science ®Google Scholar
• •In vitro studies indicated that oxovanadium(IV) complexes trigger the production of ROS in human leukaemia cells, cause Gl-arrest and inhibit donogenic growth at nanomolar concentrations.
   Google Scholar
• REUSS-BORST MA, BUHRING HJ, KLEIN G, MULLER CA: Adhesion molecules on CD34+ hematopoietic cells in normal human bone marrow and leukemia. Ann. Hematol (1992) 65:169–174.
   PubMed Web of Science ®Google Scholar
• BRADSTOCK K, MAKRYNIKOLA V, BIANCHI A, BYTH K: Analysis of the mechanism of adhesion of precursor-B acute lymphoblastic leukemia cells to bone marrow fibroblasts. Blood (1993) 82:3437–3444.
   PubMed Web of Science ®Google Scholar
• PAIETTA E: Adhesion molecules in acutemyeloid leukemia. Leak. Res. (1996) 20:795–798.
   PubMed Web of Science ®Google Scholar
• LAURIE GW, BING JT, KLEINMAN HKet al.: Localization of binding sites for laminin, heparan sulfate proteoglycan and fibronectin on basement membrane (Type IV) collagen.Biol. (1986)189:205–216.
   Google Scholar
• BURTHEM J, CAWLEY JC: Specific tissue invasion, localisation and matrix modification in hairy-cell leukemia. Leak. Lymphoma (1994) 14\(Suppl. 1):19–22.
   Google Scholar
• BASSET P, OKADA A, CHENARD MP et al.: Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. (1997) 15:535–541.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SD: Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Carr. Opin. Cell Biol. (1998) 10:602–608.
   PubMed Web of Science ®Google Scholar
• JOHNSEN M, LUND LR, ROMER J, ALMHOLT K, DANO K: Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curt: Opin. Cell Biol (1998) 10:667–671.
   PubMed Web of Science ®Google Scholar
• STETLER-STEVENSON WG: The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg. Oncol Clin. N Am. (2001) 10:383–392.
   PubMedGoogle Scholar
• D'CRUZ 0J, UCKUN FM: Bis(4,7-dimethyl and 5-dinitro-1,10-phenanthroline) sulfato-oxovanadium (IV)-mediated in vivo male germ cell apoptosis. Appl. Toxicol (2001) 21:331–339.
   Google Scholar
• •This study evaluated the ability of cytotoxic oxovanadium(IV) complexes to induce germ cell apoptosis in vivo in the mouse model and identified metvan as a potential candidate for the treatment of human testicular germ cell tumours.
   Google Scholar
• NARLA RK, CHEN CL, DONG Y, UCKUN FM: In vivo antitumor activity of bis(4,7-dimethy1-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO (SO4) (Me2-Phen)2]). Clin. Cancer Res. (2001) 7:2124–2133.
   PubMed Web of Science ®Google Scholar
• •This report indicates that metvan exhibits potent cytotoxic, apoptotic, antiadhesive, antimigratory, and anti-invasive properties against human gjioblastoma and breast cancer cells. Metvan was non-toxic, has favourable pharmacokinetics, exhibits significant anticancer activity, delays tumour progression and prolongs survival in immunodeficient mice.
   Google Scholar
• MERZAK A, KOOCHEKPOUR S, PILKINGTON GJ: Adhesion of human glioma cell lines to fibronectin, laminin, vitronectin and collagen I is modulated by gangliosides in vitro. Cell Adhes. Commun. (1995) 3:27–43.
   PubMed Web of Science ®Google Scholar
• CHINTALA SK, RAO JK: Invasion of human glioma: Role of extracellular matrix proteins. Front. BioscL (1996) 1:324–339.
   PubMedGoogle Scholar
• PILKINGTON GJ, BJERKVIG R, DE RIDDER L, KAAIJK P: In vitro and in vivo models for the study of brain tumour invasion. Anticancer Res. (1997) 17:4107–4109.
   PubMed Web of Science ®Google Scholar
• SCHIFFER D, CHIO A, GIORDANA MT, MAURO A, MIGHELI A, VIGLIANI MC: The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study. Acta Neuropathol (Berl) (1989) 77:369–378.
   PubMed Web of Science ®Google Scholar
• NAGANO N, SASAKI H, AOYAGI M, HIRAKAWA K: Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol 04(1993) 86:117–125.
   PubMed Web of Science ®Google Scholar
• BROWN LF, GUIDI AJ, SCHNITT SJ et al.: Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin. Cancer Res. (1999) 5:1041–1056.
   PubMed Web of Science ®Google Scholar
• BOLTEUS AJ, BERENS ME, PILKINGTON GJ: Migration and invasion in brain neoplasms. Carr. Neurol NeuroscL Rep. (2001) 1:225–232.
   PubMedGoogle Scholar
• CHASTEEN ND: Vanadium-protein interactions. Met. Ions Biol. Syst. (1995) 31:231–247.
   PubMedGoogle Scholar
• MICHELE DE, THOMSEN D, LOUTERS LL: Vanadates form insoluble complexes with histones. Biochimie (1997) 79:457–462.
   PubMed Web of Science ®Google Scholar
• DAVIES B, MORRIS T: Physiological parameters in laboratory animals and humans. Pharm. Res. (1993) 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• HARRINGTON KJ, ROWLINSON-BUSZA G, USTER PS, STEWART JS: Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother. Pharmacol (2000) 46:10–18.
   PubMed Web of Science ®Google Scholar
• SAKURAI H, TAMURA H, OKATANI K: Mechanism for a new antitumor vanadium complex: hydroxyl radical-dependent DNA cleavage by 1, 10-phenanthroline-vanadyl complex in the presence of hydrogen peroxide. Biochem. Biophys. Res. Commun. (1995) 206:133–137.
   PubMed Web of Science ®Google Scholar
• NARLA RK, DONG Y, UCKUN FM: Apoptosis inducing novel anti-leukemic agent, bis(4,7-dimethy1-1,10 phenanthroline) sulfatooxovanadium (IV) NO (SO4) (Me2-Phen)2] depolarizes mitochondrial membranes. Leak. Lymphoma (2001) 41:625–634.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated that the mitochondrial permeability transition takes place during metvan-induced apoptosis and is mediated through induction of ROS and depletion of glutathione.
   Google Scholar
• D'CRUZ 0J, DONG Y, UCKUN FM: Spermicidal activity of oxovanadium(IV) complexes of 1, 10-phenanthroline, 2,2'-bipyridyl, 5'-bromo-2'- hydroxyacetophenone and derivatives in humans. Biol. Reprod. (1999) 60:435–444.
   PubMed Web of Science ®Google Scholar
• •This study reports that oxovanadium(IV) complexes exhibit potent spermicidal activity by rapidly and irreversibly immobilising sperm and inducing apoptosis at low micromolar concentrations. The spermicidal activity was shown to be mediated by the ROS-inducing ability of oxovanadium(IV) complexes.
   Google Scholar
• SAKURAI H, NAKAI M, MIKI T, TSUCHIYA K, TAKADA J, MATSUSHITA R: DNA cleavage by hydroxyl radicals generated in a vanadyl ion-hydrogen peroxide system. Biochem. Biophys. Res. Commun. (1992) 189:1090–1095.
   PubMed Web of Science ®Google Scholar
• SHI X, WANG P, JIANG H, MAO Y, AHMED N, DALAL N: Vanadium(IV) causes 2'-deoxyguanosine hydroxylation and deoxyribonucleic acid damage via free radical reactions. Ann. Clin. Lab. Sci. (1996) 26:39–49.
   PubMed Web of Science ®Google Scholar
• OLAS B, WACHOWICZ B: Modulation of cisplatin toxicity in blood platelets by glutathione depletion. Anti-Cancer Drugs (1998) 9:473–478.
   PubMed Web of Science ®Google Scholar
• PU YS, HOUR TC, CHEN J, HUANG CY, GUAN JY, LU SH: Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anti-Cancer Drugs (2002) 13:293–300.
   PubMed Web of Science ®Google Scholar
• MACARA IG, GRAY GM: Vanadate-activated calcium influx in A431 cells is dependent on the plasma membrane potential. I Cell Biochem. (1987) 34:125–128.
   PubMed Web of Science ®Google Scholar
• SAMET JM, SILBAJORIS R, WU W, GRAVES LM: Tyrosine phosphatases as targets in metal-induced signaling in human airway epithelial cells. Am. Respir. Mol Biol. (1999) 21:357–364.
   PubMed Web of Science ®Google Scholar
• SCHIEVEN GL, WAHL AF, MYRDAL S, GROSMAIRE L, LEDBETTER JA:
   Google Scholar
• •• Lineage-specific induction of B cell apoptosis and altered signal transduction by the phosphotyrosine phosphatase inhibitor bis(maltolato)oxovanadium(IV). Biol. Chem. (1995) 270:20824–20831.
   Google Scholar
• DAWSON G, KILKUSJ, SCHIEVEN GL: Selective phosphotyrosine phosphatase inhibition and increased ceramide formation is associated with B-cell death by apoptosis. FEBS Lett. (2000) 478:233–236.
   PubMed Web of Science ®Google Scholar
• WINKELHAUS S, HAUSER M: Ortho-vanadate affects both the tyrosination/ detyrosination state of spindle microtubules and the organization of XTH-2 spindles. Eur. J. Cell Biol. (1997) 73:306–315.
   PubMed Web of Science ®Google Scholar
• NAVARA CS, BENYUMOV A, VASSILEV A, NARLA RK, GHOSH P, UCKUN FM: Vanadocenes as potent anti-proliferative agents disrupting mitotic spindle formation in cancer cells. Anti-Cancer Drugs (2001) 12:369–376.
   PubMed Web of Science ®Google Scholar
• •This report provides evidence that vanadocenes block cell division in human cancer cells by disrupting bipolar spindle and arrest at the G2/M transition of the cell cycle.
   Google Scholar
• AULD DS: Use of chelation agents to inhibit enzymes. Methods EnzymoL (1988) 158:110–114.
   PubMed Web of Science ®Google Scholar
• SUN Y, BIAN J, WANG Y, JACOBS C: Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene (1997) 14:385–393.
   PubMed Web of Science ®Google Scholar
• KASTAN MB, CANMAN CE, LEONARD CJ: P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev (1995) 14:3–15.
   PubMed Web of Science ®Google Scholar
• LIEBERMANN DA, HOFFMAN B, STEINMAN RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene (1995) 11:199–210.
   PubMed Web of Science ®Google Scholar
• PARKER HUGHES INSTITUTE: U56432941 (2002).
   Google Scholar
• ••A structure-activity relationship studydescribing the anticancer activity of 25 bis(cydopentadienyOvanadiurn(IV) and 14 oxovanadium(IV) compounds and several prototypical oral and intravenous dosage forms for therapeutic and prophylactic use in humans.
   Google Scholar